Canaccord raised the firm’s price target on Inari Medical to $71 from $55 and keeps a Buy rating on the shares. The firm said they beat Q2 results but costs were higher than expected while the guidance raise reflects just the Q2 beat and is back-end loaded.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NARI: